Philip has more than 20 years' experience writing about companies, general finance and investing matters for a variety of publications. His career has involved spells at the Investors Chronicle, where he was small companies and companies editor, Investors Week and most recently as editor of online financial news wire Sharecast. He has also contributed to a wide range of financial-focused publications on a freelance basis.
If successful, a new drug application is expected to be lodged by end 2019.
The Saskatchewan Research Council (SRC) found the proprietary design process was successful in recovering up to 83.7% lithium
Bumper numbers had been predicted due to a bounce in trading following Donald Trump’s election
Editas is one of three companies currently locked in a courtroom battle over the ownership of the gene-editing technique CRISPR
As a result of the dispute, Qualcomm said it expects no patent –license revenue for iPhones in this quarter.
Asiamet is working towards a bankable feasibility study at BKM and is looking for funds to help finance this.
Opdivo sales jumped by 60% in the three months to March
The Pepsi Cola owner has been on the back foot after being lambasted for poor taste after an advert last month